Discover our impact all over the world.

Numbers displayed on the map are a representation of the activity in each country. Once you use the filter selections below, you will have the opportunity to explore projects and faculty in each country.

Projects + Faculty = Activity Number



Projects 883
Countries 147
Faculty 447
Health Topics 145

Filter from the selections below

Clear All Filters

HVTN 100. A phase 1-2 randomized, double-blind, placebo-controlled clinical trial of clade C ALVAC-HIV (vCP2438) and Bivalent Subtype C gp120/MF59 in HIV-uninfected adults at low risk of HIV infection.

HVTN 100 forms part of the Phase 3 programme and will be testing a clade C-adapted ALVAC-Bivalent gp120/MF59 vaccine regimen in South Africa, similar to that used in RV144. HVTN 100 will evaluate the safety and immunogenicity of HIV clade c DNA, and of MF59-adjuvanted calde C Env protein in healthy, HIV-uninfected adult participants. The study is using 2 different vaccines: The ALVAC-HIV (vCP2438) and Bivalent Subtype C gp120/MF59. Safety and immunongenicity data from this trial will inform a decision whether to advance the vaccine regimen to a phase 3 trial with the goal of eventual vaccine licensure.
Funding is provided by the HIV Vaccine Trials Network.

Active Dates 
02/01/2015 to 12/31/2016